Compare MSM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSM | RYTM |
|---|---|---|
| Founded | 1941 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.8B |
| IPO Year | 1996 | 2017 |
| Metric | MSM | RYTM |
|---|---|---|
| Price | $119.51 | $107.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | $96.20 | ★ $131.14 |
| AVG Volume (30 Days) | 557.9K | ★ 603.8K |
| Earning Date | 04-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $3,363,817,000.00 | N/A |
| Revenue This Year | $5.82 | $55.34 |
| Revenue Next Year | $5.26 | $86.06 |
| P/E Ratio | $39.11 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $78.80 | $74.50 |
| 52 Week High | $130.46 | $122.20 |
| Indicator | MSM | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 46.79 |
| Support Level | $118.14 | $99.14 |
| Resistance Level | $127.25 | $112.43 |
| Average True Range (ATR) | 2.89 | 4.39 |
| MACD | -0.16 | -0.71 |
| Stochastic Oscillator | 40.07 | 17.84 |
Founded in 1941, MSC Industrial Direct originally manufactured and sold cutting tools to metalworking shops in New York. Through a series of acquisitions and organic expansions, MSC has grown into an industrial distribution powerhouse with a focus on specialized metalworking products and services. The firm also distributes a wide breadth of maintenance, repair, and operations supplies. MSC primarily operates in North America, where it derives over 95% of its revenue.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.